Study on COgnition and Prognosis in the Elderly (SCOPE)

Blood Pressure

Volumn 8, Issue 3, 1999, Pages 177-183

  Hansson, Lennart ^a   Lithell, H ^b   Skoog, I ^b   Baro, F ^b   Banki C M ^b   Breteler, M ^b   Carbonin, P U ^b   Castaigne, A ^b   Correia, M ^b   Degaute, J P ^b   Elmfeldt, D ^b   Engedal, K ^b   Farsang, C ^b   Ferro, J ^b   Hachinski, V ^b   Hofman, A ^b   James, O F W ^b   Krisin, E ^b   Leeman, M ^b   De Leeuw, P W ^b   Leys, D ^b   Lobo, A ^b   Nordby, G ^b   Olofsson, B ^b   Opolski, G ^b   Prince, M ^b   Reischies, F M ^b   Rosenfeld, J B ^b   Ruilope, L ^b   Salerno, J ^b   Tilvis, R ^b   Trenkwalder, P ^b   Zanchetti, A ^b   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

Candesartan cilexetil; Cardiovascular events; Cognitive function; Elderly; Mild hypertension

Indexed keywords

CANDESARTAN HEXETIL; HYDROCHLOROTHIAZIDE;

AGED; ARTICLE; BORDERLINE HYPERTENSION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH ECONOMICS; HEART INFARCTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0032720579     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370599439715     Document Type: Article

References (34)

1. Caird FI, Cargill D. Viewpoint. Chronic brain failure: the silent epidemic. N Z Med J 1987; 100: 13-6.
2. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-76.
3. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease, part I: Effects of prolonged differences in blood pressure - evidence from nine prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
4. Breteler MMB, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: The Rotterdam study. Br Med J 1994; 308: 1604-8.
5. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol 1993; 4: 265-71.
6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program. JAMA 1991; 265: 3255-64.
7. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T. Wester P-O. Mortality and morbidity in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
8. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. Br Med J 1992; 304: 405-12.
9. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-63.
10. Skoog I. Guest editorial. Status of risk factors for vascular dementia. Neuroepidemiology 1998; 17: 2-9.
11. Skoog I. A reveiw on blood pressure and ischaemic white matter lesions. Dement Geriatr Cogn Disord 1998; 9 (Suppl 1): 13-19.
12. Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet 1994; 344: 519-21.
13. Jorm AF. The epidemiology of Alzheimer's disease and related disorders. London: Chapman & Hall, 1990.
14. Katzman R. Alzheimer's disease. N Engl J Med 1986; 314: 964-73.
15. Skoog I, Nilsson L, Palmertz B, Andreasson L-A, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med 1993; 328: 153-8.
16. Kilander L, Nyman H, Andrén B, et al. Hypertension and associated metabolic disturbances are related to cognitive impairment. A 20-year follow-up of 999 men. Hypertension 1998; 31: 780-6.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state"': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
18. Tombaugh TN, McIntyre NJ. The mini-mental state examination: A comprehensive review. J Am Geriatr Soc 1992; 40: 922-35.
19. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
20. Tatemichi TK, Foulkes MA, Mohr JP, et al. Dementia in stroke survivors in the Stroke Data Bank cohort: prevalence, incidence, risk factors, and computed tomographic findings. Stroke 1990; 21: 858-66.
21. Tatemichi TK, Desmond DW, Mayeux R, et al. Dementia after stroke: Baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992; 42: 1185-93.
22. Aronson MK, Ooi WL, Morgenstern H, et al. Women, myocardial infarction, and dementia in the very old. Neurology 1990; 40: 1102-6.
23. Sparks DL, Hunsaker JC, Scheff SW, et al. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990; 11: 601-7.
24. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-4.
25. MacMahon S. Blood pressure and the risks of cardiovascular diseases. In: Swales JD, ed. Textbook of hypertension. Oxford: Blackwell, 1994: 46-57.
26. Hansson L, Zanchetti A, Carruthers SG, et al. For the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
27. Hachinski V. Preventable senility: a call for action against the vascular dementias. Lancet 1992; 340: 645-8.
28. Forette F, Seux M-L, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-51.
29. Prince M. Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia. J Psychosomat Res 1995; 39: 525-30.
30. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med 1996; 156: 1957-65.
31. 3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res 1989; 492: 136-43.
32. Barnes NM, Champaneria S, Costall B, Kelly ME, Murphy DA, Naylor RJ. Cognitive enhancing actions of DUP 753 detected in a mouse habituation paradigm. Neuroreport 1990; 1: 239-42.
33. Elmfeldt D, George M, Hübner R, et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11 (Suppl 2): S49-53.
34. McInnes GT, O'Kane KP, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl 2): S75-80.